Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

Gilead Sciences (GILD) is currently showing above average volatility with an IV Percentile of 95% and an IV Rank of 70.73%.

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

The S&P 500 index closed higher on Monday as investors were still optimistic over trade talks between the United States and ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...